Wasatch Advisors LP Sells 20,327 Shares of AtriCure, Inc. $ATRC

Wasatch Advisors LP cut its stake in shares of AtriCure, Inc. (NASDAQ:ATRC) by 8.0% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 233,604 shares of the medical device company’s stock after selling 20,327 shares during the quarter. Wasatch Advisors LP owned 0.46% of AtriCure worth $6,536,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Geneos Wealth Management Inc. purchased a new stake in shares of AtriCure during the second quarter valued at approximately $37,000. Smartleaf Asset Management LLC increased its stake in shares of AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after buying an additional 429 shares during the period. Harbor Investment Advisory LLC purchased a new position in shares of AtriCure in the second quarter worth $40,000. Fifth Third Bancorp purchased a new position in shares of AtriCure in the first quarter worth $51,000. Finally, Global Retirement Partners LLC bought a new stake in AtriCure during the 4th quarter valued at $73,000. 99.11% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Weiss Ratings raised shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a report on Tuesday, July 28th. Wall Street Zen downgraded shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. UBS Group dropped their target price on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. Finally, Zacks Research upgraded AtriCure from a “hold” rating to a “strong-buy” rating in a report on Friday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, AtriCure presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

AtriCure Stock Performance

Shares of ATRC stock opened at $43.56 on Thursday. The stock has a fifty day moving average of $33.24 and a 200 day moving average of $31.40. AtriCure, Inc. has a 52 week low of $25.36 and a 52 week high of $43.84. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of 207.44 and a beta of 1.20. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. During the same period in the previous year, the firm earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, research analysts expect that AtriCure, Inc. will post 0.2 earnings per share for the current year.

Insider Activity

In related news, Director Karen Prange sold 3,564 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total value of $138,283.20. Following the completion of the transaction, the director directly owned 22,809 shares of the company’s stock, valued at $884,989.20. This represents a 13.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Justin J. Noznesky sold 6,182 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total transaction of $239,861.60. Following the completion of the sale, the insider owned 100,219 shares of the company’s stock, valued at $3,888,497.20. This trade represents a 5.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 47,246 shares of company stock worth $1,777,845. 4.00% of the stock is owned by company insiders.

AtriCure Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.